F-star management takes company private, two years after $161M cash exit to Sino's invoX

UK antibody developer F-star Therapeutics has become a private, independent biotech. The surprise move — announced via F-star's LinkedIn page on Thursday — comes two years after a drawn-out $161 million M&A exit ...